Mandrake Bio

Mandrake Bio is developing infrastructure for protein design and gene editing using AI-native methods. The company aims to shift biology from discovery-based approaches to engineering-driven design, focusing on creating molecular tools tailored for specific applications rather than optimizing existing enzymes.

Public-source profile · Company ownership not verified. Sources & corrections

The short feature · 2 min read

Mandrake Bio, at a glance

Company-sourced feature

Built for · Researchers, biotech companies, and investors interested in gene editing and protein design technologies.

Based on company material. Product claims are attributed to the company.

01
The problem
Traditional gene editing relies on enzymes discovered through evolution, which may not be optimal for specific applications. Existing methods often involve random protein generation or incremental optimization, limiting efficiency and precision in designing molecular tools for targeted functions.
Sources [1]
02
The product approach
Mandrake Bio designs proteins and gene-editing systems from scratch, encoding biological and biophysical requirements directly into its AI models. The company validates function through purpose-built assays, using experimental results to refine subsequent designs. This approach reportedly achieves double-digit experimental hit rates.
Sources [1]
03
What stands out
Unlike methods that generate proteins randomly or optimize existing enzymes, Mandrake Bio’s process integrates application-specific requirements into its models upfront. The company claims this results in gene editors designed around delivery constraints, such as compact size and tissue-specific precision, rather than adapting pre-existing tools.
Sources [1]

What could be hard to replicate?

A useful product is not automatically a moat. These mechanisms need evidence of a lasting advantage.

Data advantage
Company claim
Mandrake Bio operates an on-premises, interconnected DNA-protein database (TerraBase) with rich biological context, which supports its function-aware generative models. This proprietary data infrastructure may enable more contextually informed protein design compared to generic AI models.
Mechanism → evidence check
Does exclusive data improve the product in a way competitors cannot reproduce?
Sources [1]
Operations & scale
Company claim
The company’s in-house wet lab and partner network for functional testing allow it to validate designs iteratively, feeding results back into its models. This closed-loop system may reduce reliance on external validation and accelerate design refinement.
Mechanism → evidence check
Does operating experience create a sustained cost or execution advantage?
Sources [1]

The question to watch

The company claims its approach achieves higher experimental hit rates and application-specific precision, but independent validation of these outcomes—particularly in real-world gene-editing applications—remains limited. Further evidence is needed to assess scalability and comparative performance.

Explore the evidence · 1 source

[1] Mandrake Bio company website
Company material · checked 5/10/2026
biology. Now, we're designing what comes next. Mandrake Bio The first generation of gene editors was discovered. The next will be designed from the function…

About

Mandrake Bio is building AI-native protein design and gene editing infrastructure to turn biology from discovery into engineering.

Founders

Tanay Lohia

Profile sources, ownership & corrections

Company ownership is not verified

This profile was compiled from public sources and hasn't been verified by Mandrake Bio. Claim it to correct the details, add your team and funding history, and request review of your company information.

Compiled from news coverage, the company's own website.

Claim this listing Report a problem

ShareLinkedIn X WhatsApp